Henrik Wulff, Novo Nordisk EVP of product supply, quality and IT (Credit: Novo Nordisk)
March 7, 2024 12:45 PM EST
Manufacturing

No­vo un­like­ly to out­source API pro­duc­tion for GLP-1s but will stay en­gaged with fill-fin­ish part­ners

Reynald Castañeda

Deputy Editor

Anna Brown

News Reporter

No­vo Nordisk spelled out how it will try to catch up with the ex­tra­or­di­nary de­mand for its GLP-1 drugs, un­der­scor­ing its ra­tio­nale for its in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times